Euroopan unioni - suomi - EMA (European Medicines Agency)

h. lundbeck a/s - eptinezumab - migreenihäiriöt - kipulääkkeet - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.